Contributions
Abstract: EP1807
Type: ePoster
Abstract Category: Therapy - disease modifying - 32 Others
Introduction: BETACONNECT™ is an electronic autoinjector with communication capabilities that may help patients to remain adherent to interferon beta-1b.
Methods: Adherence (defined as completing ≥80% of prescribed injections) was assessed via autoinjector recordings over 24 weeks with visits at baseline, week 4, week 12 and week 24 in patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) who were treated with interferon beta-1b using BETACONNECT.
Results: 500 patients were enrolled with 498 in the full analysis set (median age: 44 years; 64.6% female, 28.8% completed college or university education). 474 patients (94.8%) were diagnosed with RRMS and 26 (5.2%) were diagnosed with CIS, with a median disease duration of 76.1 and 22.7 months, respectively. Median baseline EDSS score was 1.5 (N=449). Median adherence remained stable between 93.9% and 95.4% at all visits. 76.4%, 67.6%, and 81.1% of patients with non-missing data had ≥80% of planned injections recorded for study visits 1, 2, and 3, respectively. Multivariate logistic regression models indicated that higher adherence was associated with male gender, existing concomitant disease, shorter disease duration, higher SDMT score and higher satisfaction with the myBETAapp. 81.4% completed the study. The main reasons for study discontinuation were: switching to another injection method (25.8%), withdrawal of consent (22.6%) and becoming lost to follow up (17.2%). 83.4% of the patients still used BETACONNECT at their final visit.
Discussion: BetaEval Global showed a relatively high rate of adherence among patients with RRMS or CIS using BETACONNECT to administer interferon beta-1b. Additional research will explore device satisfaction and outcomes in patients using the autoinjector.
Disclosure:
- This study was supported by Bayer AG.
- F Patti served as an advisor for Almirall, Bayer, Biogen, Merck, Novartis, Sanofi Genzyme and TEVA and received grants for speaking activities from the same companies.
- M Martinez-Gines has received compensation for her contribution to the BetaEval Global study to the account of the Department of Neurology, Hospital General Universitario Gregorio Marañón-Madrid, by Bayer.
- C Norenberg is a salaried employee of Bayer AG.
- F Duarte Caron is a salaried employee of Bayer Healthcare.
Abstract: EP1807
Type: ePoster
Abstract Category: Therapy - disease modifying - 32 Others
Introduction: BETACONNECT™ is an electronic autoinjector with communication capabilities that may help patients to remain adherent to interferon beta-1b.
Methods: Adherence (defined as completing ≥80% of prescribed injections) was assessed via autoinjector recordings over 24 weeks with visits at baseline, week 4, week 12 and week 24 in patients with relapsing-remitting MS (RRMS) or clinically isolated syndrome (CIS) who were treated with interferon beta-1b using BETACONNECT.
Results: 500 patients were enrolled with 498 in the full analysis set (median age: 44 years; 64.6% female, 28.8% completed college or university education). 474 patients (94.8%) were diagnosed with RRMS and 26 (5.2%) were diagnosed with CIS, with a median disease duration of 76.1 and 22.7 months, respectively. Median baseline EDSS score was 1.5 (N=449). Median adherence remained stable between 93.9% and 95.4% at all visits. 76.4%, 67.6%, and 81.1% of patients with non-missing data had ≥80% of planned injections recorded for study visits 1, 2, and 3, respectively. Multivariate logistic regression models indicated that higher adherence was associated with male gender, existing concomitant disease, shorter disease duration, higher SDMT score and higher satisfaction with the myBETAapp. 81.4% completed the study. The main reasons for study discontinuation were: switching to another injection method (25.8%), withdrawal of consent (22.6%) and becoming lost to follow up (17.2%). 83.4% of the patients still used BETACONNECT at their final visit.
Discussion: BetaEval Global showed a relatively high rate of adherence among patients with RRMS or CIS using BETACONNECT to administer interferon beta-1b. Additional research will explore device satisfaction and outcomes in patients using the autoinjector.
Disclosure:
- This study was supported by Bayer AG.
- F Patti served as an advisor for Almirall, Bayer, Biogen, Merck, Novartis, Sanofi Genzyme and TEVA and received grants for speaking activities from the same companies.
- M Martinez-Gines has received compensation for her contribution to the BetaEval Global study to the account of the Department of Neurology, Hospital General Universitario Gregorio Marañón-Madrid, by Bayer.
- C Norenberg is a salaried employee of Bayer AG.
- F Duarte Caron is a salaried employee of Bayer Healthcare.